Compare Cipla with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs GSK PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA GSK PHARMA CIPLA/
GSK PHARMA
 
P/E (TTM) x 35.6 -80.7 - View Chart
P/BV x 4.1 12.0 34.4% View Chart
Dividend Yield % 0.5 1.3 37.6%  

Financials

 CIPLA   GSK PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
GSK PHARMA
Mar-19
CIPLA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs5863,595 16.3%   
Low Rs3571,253 28.5%   
Sales per share (Unadj.) Rs207.0184.7 112.1%  
Earnings per share (Unadj.) Rs18.626.3 70.7%  
Cash flow per share (Unadj.) Rs33.229.2 113.7%  
Dividends per share (Unadj.) Rs4.0020.00 20.0%  
Dividend yield (eoy) %0.80.8 102.9%  
Book value per share (Unadj.) Rs195.5126.3 154.8%  
Shares outstanding (eoy) m806.35169.40 476.0%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.313.1 17.3%   
Avg P/E ratio x25.392.2 27.5%  
P/CF ratio (eoy) x14.283.1 17.1%  
Price / Book Value ratio x2.419.2 12.6%  
Dividend payout %21.576.1 28.3%   
Avg Mkt Cap Rs m379,912410,626 92.5%   
No. of employees `00025.85.0 521.1%   
Total wages/salary Rs m30,2705,372 563.5%   
Avg. sales/employee Rs Th6,459.66,306.7 102.4%   
Avg. wages/employee Rs Th1,171.21,083.1 108.1%   
Avg. net profit/employee Rs Th580.2898.0 64.6%   
INCOME DATA
Net Sales Rs m166,94931,281 533.7%  
Other income Rs m3,4421,023 336.4%   
Total revenues Rs m170,39132,304 527.5%   
Gross profit Rs m32,0606,009 533.5%  
Depreciation Rs m11,747486 2,417.0%   
Interest Rs m1,9746 32,893.3%   
Profit before tax Rs m21,7826,540 333.1%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m6,3122,373 266.0%   
Profit after tax Rs m14,9954,454 336.7%  
Gross profit margin %19.219.2 100.0%  
Effective tax rate %29.036.3 79.9%   
Net profit margin %9.014.2 63.1%  
BALANCE SHEET DATA
Current assets Rs m117,03820,061 583.4%   
Current liabilities Rs m43,93114,543 302.1%   
Net working cap to sales %43.817.6 248.2%  
Current ratio x2.71.4 193.1%  
Inventory Days Days9657 168.6%  
Debtors Days Days8514 605.1%  
Net fixed assets Rs m107,42414,343 749.0%   
Share capital Rs m1,6131,694 95.2%   
"Free" reserves Rs m156,01819,704 791.8%   
Net worth Rs m157,63021,398 736.6%   
Long term debt Rs m23,6932 1,184,640.0%   
Total assets Rs m236,62639,113 605.0%  
Interest coverage x12.01,091.0 1.1%   
Debt to equity ratio x0.20 160,815.0%  
Sales to assets ratio x0.70.8 88.2%   
Return on assets %7.211.4 62.9%  
Return on equity %9.520.8 45.7%  
Return on capital %12.831.9 40.2%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,036534 10,493.6%   
Fx outflow Rs m6,7647,091 95.4%   
Net fx Rs m49,272-6,557 -751.4%   
CASH FLOW
From Operations Rs m30,6853,994 768.3%  
From Investments Rs m1,040-1,433 -72.6%  
From Financial Activity Rs m-29,488-3,584 822.9%  
Net Cashflow Rs m2,340-1,023 -228.7%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 50.7 41.0%  
Indian inst/Mut Fund % 12.2 10.2 119.6%  
FIIs % 23.7 23.8 99.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 15.4 170.1%  
Shareholders   161,166 102,036 158.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  ORCHID PHARMA  NOVARTIS  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 22, 2021 (Close)

TRACK CIPLA

CIPLA - PANACEA BIOTECH COMPARISON

COMPARE CIPLA WITH

MARKET STATS